CytomX Therapeutics (NASDAQ: CTMX) reported Q2 EPS of ($0.37), in-line with the analyst estimate of ($0.37). Revenue for the quarter came in at $18.17 million versus the consensus estimate of $18.11 million.

For earnings history and earnings-related data on CytomX Therapeutics (CTMX) click here.